← Back to headlines
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment
BeOne Medicines (ONC) announced a Q4 revenue of $1.5 billion, with $1.1 billion specifically generated from its lymphoma treatment, indicating strong performance in the pharmaceutical sector.
1 Mar, 14:59 — 1 Mar, 14:59
Sources
Showing 1 of 1 sources
